A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

• Status: Completed
• Trial end date: 2003-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Novartis
• Treatments: Maleic acid

Criteria

Inclusion Criteria:

• Male or female ,aged 30-80 years

• Clinical diagnosis of early stage idiopathic Parkinson's disease

• Experiencing two of the three following signs; bradykinesia, rigidity, and tremor

• Not currently taking any antiparkinson medication

Exclusion Criteria:

• A history of alcohol or drug abuse in the past year

• A diagnosis psychiatric illness

• Patients who currently are taking MAO inhibitors within 30 days of entering the study

• Patients who are hypersensitive to selegiline, MAO-B inhibitors, or tricyclic antidepressants

Additional inclusion/exclusion criteria may apply